Loading...
•
Dec 31, 2021
Establishment Labs Q4 2021 Earnings Report
Establishment Labs reported record fourth quarter revenue and progress in key strategic initiatives.
Key Takeaways
Establishment Labs reported a strong fourth quarter with record revenue of $35.3 million, a 31.0% increase year-over-year. Gross profit margin improved to 68.6%. The company provided 2022 revenue guidance of $155 million to $165 million, representing growth of 22% to 30%.
Fourth quarter worldwide sales reached $35.3 million, a 31.0% increase year-over-year.
Gross profit for the fourth quarter was 68.6% of revenue, compared to 54.3% for the same period in 2020.
The company launched Motiva Flora® tissue expander in Europe and CE mark countries.
2022 revenue guidance of $155 million to $165 million, an increase of 22% to 30% over 2021.
Forward Guidance
Establishment Labs anticipates another strong year in 2022 with revenue between $155 million and $165 million.
Positive Outlook
- Strong growth across all areas of the business.
- Launch of Motiva Flora® tissue expander and Aesthetic BreastRecon® program.
- Introduction of JOY™ and Ergonomix2®.
- Progress with Motiva MIA®.
- Regulatory and commercial timelines to begin selling Motiva implants in the U.S. and Chinese markets are progressing as planned.
Challenges Ahead
- Operating losses and investments in facility expansion impacted cash balance.
- Increased operating expenses due to normalized spending levels.
- Increased SG&A expenses due to personnel costs and marketing expenses.
- Net loss from operations for the fourth quarter was $9.4 million.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...